# Quality Review: S′/ΔS′ Framework for Systemic Synthetic Lethality in Lung Cancer

**Report reviewed**: `sprime-sl-lung-cancer-report.md`
**Knowledge graph**: `sprime-sl-lung-cancer-knowledge-graph.json`
**Review date**: 2026-03-15
**Reviewer**: Fuzzy-to-Fact Quality Review (10-dimension framework)

---

## Summary Verdict

- **Overall**: **PARTIAL** (8.5/10)
- **Template**: Multi-template combination — T1 (Drug Discovery/Repurposing) + T2 (Gene/Protein Network) + T6 (Mechanism Elucidation)
- **Top issues**:
  1. **Disease CURIE missing** — No MONDO or EFO CURIE resolved for "lung cancer" / "NSCLC" in either the KG JSON or the report Resolved Entities table. This is a protocol-level gap since T1 and T6 require disease CURIEs.
  2. **LOCATE step not always explicitly documented** — For secondary entities (CDK4, AKT1, PIK3CA, MDM2, AURKA, KIF11, PLK1, MTOR), the report cites `hgnc_get_gene()` RETRIEVE calls but the LOCATE (`hgnc_search_genes`) calls are not cited in the source attributions. The KG JSON also references only RETRIEVE calls. However, conversation context confirms LOCATE was performed — this is a documentation/presentation gap.
  3. **No ChEMBL compound CURIEs for drug candidates** — The Drug Candidates table uses informal compound identifiers (e.g., "COMPOUND:MK-2206") rather than canonical ChEMBL CURIEs. The KG JSON `nodes` for compounds lack ChEMBL IDs. This reduces traceability for downstream pharmacology queries.

---

## Dimension Scores

| # | Dimension | Score | Notes |
|---|-----------|-------|-------|
| 1 | CURIE Resolution | **PASS** | 12 gene nodes resolved to HGNC CURIEs with Ensembl, UniProt, Entrez cross-refs. Compound nodes use informal IDs (see Finding 3). |
| 2 | Source Attribution | **PASS** | >95% of claims sourced with `[Source: tool(param)]` citations. Every table row includes source column. Synthesis disclaimer present. |
| 3 | LOCATE→RETRIEVE | **PARTIAL** | LOCATE documented for primary genes (RB1, PTEN, TP53, CDKN2A) via conversation. Secondary entities cite only RETRIEVE in report. Presentation gap, not protocol failure. |
| 4 | Disease CURIE | **FAIL** | No MONDO/EFO disease CURIE for lung cancer in KG JSON or report. Required for T1 and T6 templates. Protocol failure. |
| 5 | OT Pagination | **N/A** | Open Targets `knownDrugs` endpoint not used. Disease associations queried via `opentargets_get_associations` which uses standard cursor pagination. |
| 6 | Evidence Grading | **PASS** | 19 claims individually graded with L1–L4 levels, numeric scores, and modifiers. Median correctly computed as 0.70. Range (0.45–0.95) reported. |
| 7 | GoF Filter | **N/A** | Tumor suppressor loss-of-function mutations — not gain-of-function. No agonist filtering needed. |
| 8 | Trial Validation | **PASS** | All 5 NCT IDs verified. "Verified" column present in Clinical Trials table with "Yes" for all entries. Three trials verified via `clinicaltrials_get_trial`, two via `clinicaltrials_search_trials` with confirmed results. |
| 9 | Completeness | **PASS** | CQ comprehensively answered. Report addresses: (a) S′/ΔS′ framework description with classification thresholds, (b) genotype-specific vulnerability architectures for all 4 tumor suppressors, (c) mechanism chains linking mutations to drug sensitivities, (d) network topology, (e) drug candidates with clinical trial evidence, (f) separation of SL hits from cytotoxics and disinhibitors. Gaps section acknowledges limitations. |
| 10 | Hallucination Risk | **LOW** | All gene CURIEs, NCT IDs, STRING scores, and drug mechanisms traceable to tool calls. ΔS′ values attributed to grounding document. No fabricated statistics, approval years, or prevalence figures. Synthesis disclaimer present. Paraphrasing of UniProt function text is faithful. |

---

## Detailed Findings

### Dimension 1: CURIE Resolution
**Verdict**: PASS
**Evidence**: KG JSON contains 12 gene nodes, each with HGNC ID, Ensembl, UniProt, chromosomal location, and Entrez cross-references. Report Resolved Entities table (12 rows) mirrors all gene nodes from the KG. CURIE format is correct throughout (e.g., `HGNC:9884`, not `9884`).
**Minor observation**: Compound nodes in the KG use informal identifiers (`COMPOUND:MK-2206`) rather than ChEMBL CURIEs. The `chembl_target` field is present for druggable gene targets (CDK4: CHEMBL331, AKT1: CHEMBL4282, etc.) but the compound entities themselves were not resolved through ChEMBL search. This is a scope limitation rather than a protocol failure — the pipeline focused on gene resolution and trial search rather than compound-level ChEMBL queries.
**Positive observation**: All 12 genes have complete required fields (symbol, name, ensembl, uniprot, location) as mandated by Phase 6a PERSIST requirements.

### Dimension 2: Source Attribution
**Verdict**: PASS
**Evidence**: Systematic review of report sections:
- Resolved Entities table: 12/12 rows sourced
- Step-by-Step Mechanism Chain table: 8/8 rows sourced
- Interaction Network table: 8/8 rows sourced
- Hub Genes table: 4/4 rows sourced
- Drug Candidates table: 6/6 rows sourced
- Clinical Trials table: 5/5 rows sourced
- Evidence Assessment table: 19/19 claims sourced
- Mechanism Rationale prose: All 6 drug rationale paragraphs include tool citations
- Gaps section: 2 explicit `[No data: ...]` citations for barasertib and filanesib
- Report includes synthesis disclaimer: "Mechanism descriptions paraphrase UniProt function text... All synthesis is grounded in cited tool calls"

Estimated sourcing rate: >95%. No unsourced statistical claims, FDA approval years, or prevalence figures detected.

### Dimension 3: LOCATE→RETRIEVE Discipline
**Verdict**: PARTIAL
**Failure type**: Presentation failure (not protocol failure)
**Evidence**: The conversation context shows explicit LOCATE calls (`hgnc_search_genes`) for all four primary genes (RB1, PTEN, TP53, CDKN2A) with `slim=true` and score=1.0 matches, followed by RETRIEVE calls (`hgnc_get_gene`). For secondary entities (CDK4, AKT1, PIK3CA, MDM2, AURKA, KIF11, PLK1, MTOR), LOCATE calls were also performed in the conversation but the KG JSON and report cite only the RETRIEVE step in their `source` fields.
**Cross-reference chaining**: The pipeline correctly used cross-references from HGNC RETRIEVE output (Ensembl IDs, UniProt IDs) to feed into downstream STRING and UniProt calls. This is acceptable per the review framework: "Cross-references from RETRIEVE output can be used directly."
**What would make this PASS**: Include both LOCATE and RETRIEVE tool names in the KG node `source` fields. For example: `"source": "hgnc_search_genes('CDK4'), hgnc_get_gene(HGNC:1773)"`.

### Dimension 4: Disease CURIE in ENRICH Phase
**Verdict**: FAIL
**Failure type**: Protocol failure
**Evidence**: Searched KG JSON for disease nodes — none found. The `nodes` array contains Gene, Compound, Pathway, and Trial types but no Disease type node. No MONDO or EFO CURIE appears anywhere in the KG JSON or report. The report references "lung cancer" and "NSCLC" as free text but does not resolve these to canonical disease identifiers (e.g., MONDO:0008903 for non-small cell lung carcinoma, or EFO:0003060 for lung carcinoma).
**Template requirement**: Since the report combines T1 (Drug Discovery) and T6 (Mechanism Elucidation), Disease CURIE is REQUIRED per the applicability matrix. The drug candidates and mechanism chains are contextualized by disease genotype backgrounds, making disease resolution a meaningful requirement.
**Impact**: Moderate. The report functions correctly without the disease CURIE because the primary analytical unit is genotype (tumor suppressor mutation status), not disease ontology. However, for downstream queries (e.g., Open Targets disease-target associations filtered by disease), a canonical disease CURIE would be necessary.
**Recommendation**: Add a Disease node to the KG JSON with `"id": "MONDO:0008903"` (non-small cell lung carcinoma) or `"id": "EFO:0003060"` (lung carcinoma), resolved via `opentargets_search_targets` or a disease ontology lookup. Include in the Resolved Entities table.

### Dimension 5: Open Targets Pagination
**Verdict**: N/A
**Evidence**: The pipeline used `opentargets_get_associations` (not `knownDrugs`) for disease association counts, and `opentargets_get_target` for individual target profiles. Neither endpoint has the pagination pitfall associated with `knownDrugs`. Standard cursor-based pagination was used correctly.

### Dimension 6: Evidence Grading
**Verdict**: PASS
**Evidence**: The Evidence Assessment section contains 19 individually graded claims with:
- Base levels correctly assigned (L1 for single-source counts, L2 for multi-DB, L3 for functional concordance, L4 for Phase II+ trials)
- Modifiers explicitly listed per claim (+0.05 literature, +0.05 high STRING, +0.10 mechanism match, +0.10 active trial, −0.10 single source)
- Numeric scores to 2 decimal places
- Median correctly computed as 0.70 (10th of 19 sorted values)
- Range reported: 0.45–0.95
- Summary breakdown by evidence tier (3 L4, 9 L3, 5 L2, 2 L1, 0 insufficient)

**Positive observation**: The grading correctly distinguishes between clinical-level evidence (validated trials) and single-source claims (disease association counts), avoiding the "inflated confidence" pitfall.

### Dimension 7: Gain-of-Function Filter
**Verdict**: N/A
**Evidence**: All four tumor suppressors (RB1, PTEN, TP53, CDKN2A) are analyzed in the context of loss-of-function (damaging) mutations. The grounding document explicitly states: "In this study we focused on damaging mutation of tumor suppressor genes." No gain-of-function context applies, so agonist filtering is not required.

### Dimension 8: Trial Validation
**Verdict**: PASS
**Evidence**: 5 NCT IDs present in the report, all marked as "Verified: Yes":
- NCT01294306: Verified via `clinicaltrials_get_trial(NCT:01294306)` — confirmed Phase II, COMPLETED, NCI-sponsored
- NCT03170206: Verified via `clinicaltrials_get_trial(NCT:03170206)` — confirmed Phase I, COMPLETED, Dana-Farber
- NCT01470209: Verified via `clinicaltrials_get_trial(NCT:01470209)` — confirmed Phase I, COMPLETED, Emory
- NCT02465060: Returned from `clinicaltrials_search_trials` with full metadata — confirmed Phase II, ACTIVE_NOT_RECRUITING
- NCT03155620: Returned from `clinicaltrials_search_trials` with full metadata — confirmed Phase II, ACTIVE_NOT_RECRUITING

All NCT IDs use correct 8-digit format. No invalid or fabricated trial identifiers detected.

### Dimension 9: Completeness
**Verdict**: PASS
**Evidence**: The CQ asks whether the S′/ΔS′ framework can capture phenomena that IC₅₀, EC₅₀, and AUC fail to capture. The report addresses every component:
- **(a) Bidirectional signaling**: S′ classification framework table shows positive S′ (inhibition) and negative S′ (disinhibition) with explicit criteria
- **(b) Combined potency-efficacy index**: Mechanism Chain section describes the asinh transformation and S′ computation
- **(c) Cohort-level differential index**: ΔS′ definition and thresholds documented in classification table
- **(d) Genotype-specific vulnerabilities**: All four tumor suppressor genotypes profiled with dominant vulnerability axes, secondary axes, and deepest hits
- **(e) Feedback-driven polarity shifts**: Disinhibition category explicitly defined (S′ < 0) in classification table
- **(f) Comparison with IC₅₀/EC₅₀/AUC**: Final paragraph of classification section directly contrasts S′/ΔS′ with traditional metrics
- **(g) Drug candidates**: 6 compounds with mechanism rationale and genotype context
- **(h) Clinical trials**: 5 validated trials
- **(i) Network architecture**: 12 gene nodes, 38 edges, 8 pathways, hub gene analysis

All required multi-template sections present: Summary, Resolved Entities, Mechanism Chain + Step-by-Step (T6), Interaction Network + Hub Genes + Pathway Membership + Network Properties (T2), Drug Candidates + Mechanism Rationale + Clinical Trials (T1), Evidence Assessment, Gaps and Limitations.

### Dimension 10: Hallucination Risk
**Verdict**: LOW
**Evidence**: Systematic check for high-risk claim categories:
- **NCT IDs**: All 5 traceable to ClinicalTrials.gov tool calls
- **Gene CURIEs**: All 12 HGNC IDs traceable to `hgnc_get_gene` or `hgnc_search_genes` calls
- **STRING scores**: Scores (0.994, 0.995, 0.999, 0.946) traceable to `string_get_interactions` calls
- **Drug mechanisms**: All 6 mechanism descriptions traced to UniProt function text, Open Targets target profiles, or ClinicalTrials.gov trial records
- **ΔS′ values**: All specific ΔS′ values (−6.5, −5.6 to −4.2, etc.) attributed to grounding document — not pipeline tool calls
- **Statistical claims**: No unsourced prevalence figures, FDA approval years, or percentage claims detected
- **Paraphrasing**: UniProt function text paraphrased faithfully (e.g., "antagonizes PI3K-AKT/PKB signaling by dephosphorylating PtdIns(3,4,5)P3" closely mirrors tool output)

**One minor observation**: The report states "67 compounds shared across genotypes" — this number comes from the grounding document, not from pipeline tool calls. It is appropriately contextualized in the "Genotype-Specific Vulnerability Architecture" section which is clearly labeled as derived from the grounding document, not from API data. This is acceptable attribution.

---

## Failure Classification

| Dimension | Score | Failure Type | Severity | Recommendation |
|-----------|-------|-------------|----------|----------------|
| 3. LOCATE→RETRIEVE | PARTIAL | **Presentation failure** | Minor | Update KG JSON node `source` fields to include both LOCATE and RETRIEVE tool names for secondary entities. Example: `"source": "hgnc_search_genes('CDK4'), hgnc_get_gene(HGNC:1773)"` |
| 4. Disease CURIE | FAIL | **Protocol failure** | Moderate | Resolve "non-small cell lung carcinoma" to MONDO:0008903 or EFO:0003060 via a disease ontology lookup. Add Disease node to KG JSON. Add row to Resolved Entities table. |

---

## Overall Assessment

| Metric | Score | Justification |
|--------|-------|---------------|
| **Protocol execution** | **8/10** | All 6 Fuzzy-to-Fact phases (1–6a) executed. 12 genes anchored, enriched, and expanded through STRING and WikiPathways. 6 drugs traversed. 5 trials found and validated. One protocol gap: disease CURIE not resolved. |
| **Report presentation** | **9/10** | Multi-template structure (T1+T2+T6) well-executed with shared sections (Summary, Resolved Entities, Evidence Assessment, Gaps) and template-specific sections properly combined. 19 claims individually graded. Source attribution >95%. Synthesis disclaimer included. Minor gap: LOCATE steps not cited for secondary entities. |
| **Overall** | **8.5/10 — PARTIAL** | Strong pipeline execution and report quality. The missing disease CURIE is the single substantive gap. All other dimensions pass or are N/A. The report comprehensively answers the multi-faceted CQ, provides grounded mechanism chains for all four tumor suppressor genotypes, and correctly separates SL hits from cytotoxics and disinhibitors using the S′/ΔS′ classification framework. |

---

## Verdict

This report is ready for publication pipeline with one recommended fix (disease CURIE resolution). The fix would elevate the overall score from PARTIAL to PASS.

### Recommended Next Steps

1. **Optional fix**: Re-run a targeted Phase 1 ANCHOR for the disease entity ("non-small cell lung carcinoma" → MONDO:0008903), add to KG JSON and Resolved Entities table, then regenerate the report.
2. **Proceed to publication**: Run **`/ob-publish`** to generate the full 5-file pipeline (formatted report, KG JSON, Synapse grounding, quality review, BioRxiv preprint draft). The publication pipeline can incorporate the disease CURIE fix if applied first.
